Latest Safety News

Radiopharm Theranostics has inked a clinical supply agreement with Cyclotek to support its Phase 1 trial of RAD 402, a novel radiotherapeutic targeting prostate cancer, set to commence in Australia in late 2025.

Collins Foods Limited reported record revenue of $1.52 billion for FY25, up 2.1%, but statutory net profit plunged 88.5% due to significant impairments and wage provisions. The company declared a fully franked final dividend of 15 cents per share, signaling confidence despite challenges.

Amplia Therapeutics has secured US ethics approval to launch a Phase 2 trial combining its drug narmafotinib with FOLFIRINOX chemotherapy for advanced pancreatic cancer, marking a key step in its clinical development.

Virgin Australia Holdings Limited is set to list on the ASX, raising $685 million through a mix of new and existing shares, showcasing its transformation journey and strategic partnership with Qatar Airways.

HITIQ Limited has closed its pro-rata rights issue, raising $360,426 before costs, and is now focusing on placing the remaining shortfall of shares within three months.

Ronin Resources Limited updates ASX on delayed exploration activities and relinquished projects, citing socio-political challenges and market conditions. The company anticipates key licence grants by August 2025 and confirms compliance with listing rules while seeking new opportunities.

Tryptamine Therapeutics has secured ethics approval to begin a pioneering clinical trial of TRP-8803, an IV-infused psilocin treatment, targeting adult patients with Binge Eating Disorder. The trial aims to evaluate safety and efficacy, with initial results expected by the end of 2025.

Vection Technologies has secured a $2.6 million contract to co-develop SAFE-XR, an AI-powered safety compliance platform using augmented reality and wearable tech for industrial inspections in Italy.

X2M Connect has secured a $3 million deal to supply 100,000 IoT-connected personal safety devices for Seoul’s 2025 Smart City initiative, with potential to scale to one million units.

PYC Therapeutics has gained FDA alignment on the design of its pivotal Phase 2/3 trial for VP-001, a promising treatment for the rare childhood blindness RP11. The regulator accepted the trial’s sham control arm and primary endpoints, setting the stage for a critical next step toward drug approval.

Immutep reports promising Phase I results for IMP761, a novel LAG-3 agonist antibody demonstrating significant T cell inhibition and a clean safety profile, advancing hopes for new autoimmune disease treatments.

EV Resources has appointed Miguel Barahona as President of its Mexican subsidiary to lead the restart of the Los Lirios open pit antimony mine, signalling a strategic push to advance its operations in Oaxaca.